Company intelligence / Profile preview
Prothione
Franklin, Tennessee, United Statesif200.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Prothione LLC has developed a pro-glutathione therapy in capsule form that demonstrated positive results in a Phase II clinical trial for mild to moderate COVID‑19. The trial showed statistically significant reductions in viral load and time to clinical resolution compared to placebo. The product was safe and well-tolerated. An over-the-counter version called Immune Formulation 200® (IF200) has been approved by the Rwanda FDA and is available for sale in the US[1][3].
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Small molecule (amino acid-based therapy)Nutraceutical
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Planning collaborations for Phase III trials; no major pharma partnerships disclosed[3]
Beyond the preview
Go deeper on Prothione.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prothione.